Since studies have indicated that combinations of different classes of RAF inhibitors could be synergistic in both RAF WT and BRAF V600E cancer cells (Rukhlenko et al. 2021), we also compared the efficacy of combining type 2 RAFi with type 1 RAFi (dabrafenib and vemurafenib) or with MEKi (Figure S4I-K). This evidence concerns the gene BRAF and cancer.